Anthony Fauci: Frenemy of the People, First of Two Parts
For Fauci, fatal diseases are "where the action is," as opposed to diseases that are "just annoying." The first in a two-part deconstruction of Fauci's step-by-step disappearing of ME
One Man’s Path to Recovery—Not a Straight Line
ME, cancer, stroke: the trifecta faced by Tom Greer. His struggle to recover from all three was not a straight path. Last in a series.
One Patient's Recovery, Part Two
Sudden onset ME, cancer, a major stroke. Tom Greer must learn to walk and talk again, but his real challenge is ME. The story of one man's come back.
Recovery: One Patient's Saga
A hard-won career in voice acting nearly destroyed by the onset of ME, followed by cancer and a major stroke. An unlikely story of recovery from all three.
Francis Collins and the Zombie Apocalypse, Part Two
Collins outlines the historical events that piqued his interest in ME and offers his medical hypotheses about the existence of multiple, if unidentified, subsets.
Francis Collins and the Zombie Apocalypse, Part One
A Poor Showing by Francis Collins at the NIH Accelerating Research Conference.
Origins of the Damning Label, "Extremist"
In 2011, Simon Wessely began whining about death threats. The UK press loved it. The word extremist lingers to this day
An introduction to Dr. David Bell
"I can't wait to tell my farmers they have the Yuppie flu," were among the first words David Bell of Lyndonville, NY said to me when I met him in 1987.
Anatomy of a Missed Opportunity, Part Two
Congress has the ability, (Rep. Jerrold) Nadler said, to "mandate that [CDC] research CFS as a contagious, viral disease." How Nadler tried to help tame the CDC in 1996.
Francis Collins: Should M.E. Sufferers Care Whether He Leads the NIH? (Part Two)
The struggle to recognize M.E. as a serious disease and fund it appropriately: Francis Collins has failed on both counts.
NIH Director Francis Collins: A Trump Fave or A PlaceHolder? And Does it Matter? (Part One)
Should Francis Collins' fate matter to M.E. sufferers? A report on the politics of leadership at NIH and the opaque Trump agenda.